Acticor Sky DR-T 481987; Rivacor Sky DR-T 481982; Rivacor Rise DR-T 482018; Rivacor Aura DR-T 482014
Biotronik, Inc. · Decision date Oct 9, 2026
What did the FDA approve?
The FDA record lists this as a real-time process supplement under PMA P000009/S132, with the stated change being a battery separator pocket material change and a new additive to the battery electrolyte. The device category given is implantable dual-chamber defibrillator (product code MRM, Cardiovascular), and the applicant is Biotronik, Inc. The supplement is tied to P000009 by the identifier; the record does not describe the original PMA's full scope, so that scope is not established here.
The decision is recorded as APPR with a date of 2026-10-09. The record does not state the quantities, formulations, test methods, or evidence relied on, so the safety or performance basis for the decision cannot be assessed from these fields. It also does not show which of the four named product lines received which change. A supplement is not an approval of the whole system, and the described purpose is the source's statement rather than independent proof of safety or clinical effectiveness.
FDA approval order statement
battery separator pocket material change and new additive to battery electrolyte.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 9, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P000009/S132
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- Decision code
- APPR
- Decision date
- Oct 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P000009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P000009 · Original PMA
PHYLAX AV ICD SYSTEM
P000009/S132 received
Application receipt date recorded by FDA.
P000009/S130 · Related supplement
PSW 2601.U, NEO 2601.U, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T
P000009/S124 · Related supplement
Ilivia Neo 7 DR-T 429529; Intica Neo 7 DR-T 429558; Intica Neo 5 DR-T 429568
P000009/S133 · Related supplement
Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T, Acticor 7 DR-T, Rivacor 7 DR-T, Rivacor 5 DR-T
P000009/S132 · FDA decision
Real-Time Process
P000009/S134 · Related supplement
Intica Neo 7 DR-T DF-1 ProMRI, Intica Neo 5 DR-T DF-1 ProMRI
P000009/S128 · Related supplement
BIOexpress
P000009/S135 · Related supplement
Ilivia Neo 7 DRT, Intica Neo 7 DRT, Intica Neo 5 DRT, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aur
Timeline entries are records held by MedtechLedger for P000009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PHYLAX AV ICD SYSTEMP000009 | Biotronik, Inc. | PMA approval | Sep 29, 2000 | FDA |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP000009/S128 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MRM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP050023/S209 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P000009/S132
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



